A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.

Clinical trial NCT02417285 · COMPLETED

Trial details

NCT number: NCT02417285
Sponsor: Celgene
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Lymphoma, Large B-Cell, Diffuse Lymphoma, Non-Hodgkin

Start date: 2015-05-22
Primary completion: 2019-05-27
Enrollment: 75

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.